Presented at #ESMO25: Among participants with advanced pheochromocytoma or paraganglioma, belzutifan showed durable antitumor activity and a reduced need for antihypertensives, although most participants had treatment-related adverse events. Full LITESPARK-015 phase 2 trial

#ESMO25 | #NETs ASPEN: AS vs surgery in ≤2 cm NF-PanNETs 🧩 87% on AS 🧩 5-yr growth 16.7% | Liver mets 0.3% ⚕️ 16% severe post-op issues, no deaths 💡 AS and surgery OS similar – AS safe for most ≤2 cm NF-PanNETs ✅ ESMO - Eur. Oncology OncoAlert

#ESMO25 | #NETs LITESPARK-015 – Belzutifan (HIF-2α inhibitor) in advanced PPGL 🧩 ORR 26% | DCR 85% | mPFS 22 mo | mOS NR 🩸 30% ↓ in antihypertensive medication ≥6 mo ⚕️ Grade 3–4 TRAEs 46% (mostly anemia, hypoxia), no grade 5 💡 Durable responses with manageable safety ✅

More research and novel agents needed EP-PDNEC #ESMO25 Promising options on the horizon.

The results of the COMPETE trial (LU-177 DOTATOC vs. everolimus is mostly second line therapy (small subset 1st line). Radioligand therapy superior to everolimus. #ESMO25 Jaume Capdevila

PRODIGE 81/FFCD 2101 - TRIPLET HCC: Adding IPI to ATEZO + BEV in 1L uHCC #ESMO25 #ESMOAmbassadors 👉ORR: 30 vs 27.4% 👉mPFS: 8.0 vs 9.6 mo 👉mOS: CC vs XX mo 🧐No benefit for adding IPI, surprisingly clear negative..not enough anti-CTL4? @myesmo

Day 2 at #ESMO25 – Berlin 🇩🇪 A truly inspiring session with Dr. Mairéad McNamara and Dr. Banerjee — outstanding talks on advancing patient-centered oncology and translational impact. Grateful for the insightful discussions and the chance to learn from such leading experts. #ESMO

Great educational session on high grade NENs today 🦓rare but a real entity to definitely face ‼️conventional therapies and new options 🚨multidisciplinary team and dedicates approaches

GFH375: KRAS G12Di targets both ‘on’ & ‘off’ states #PDAC #ESMO2025 OncoAlert ➡️68% >|= 2 lines tx ➡️ORR 41%; mPFS 5.6mths ➡️mOS NR; most AEs grade 1/2 ➡️ctDNA - high rates KRAS(not~90%), low tumour suppressor rates

HRS-4642: KRAS G12D specific inh ➡️30 pts with first-line GnP ➡️ORR 63% ➡️87% >|=grade 3 AEs - most haem ‼️imp for trial design of combos ?sequencing ? Maintenance ➡️ctDNA role emerging ? Adaptive designs #esmo2025 #PDAC OncoAlert

Richard Finn presents the results of phase 3 IMbrave152/SkYSCRAPER-14 study at #ESMO25 Anti-TIGIT tiragolumab does not add benefit to atezolizumab-bevacizumab for patients with advanced #HCC #ESMOAmbassadors ESMO - Eur. Oncology

🚨 Don’t miss! #ESMO25 | #UpperGI Mini Oral Session 2 🕣 08:30–10:00 1️⃣ IKF-035/ABC-HCC: Atezo + Bev vs TACE in intermediate HCC (Phase IIIb) 2️⃣ TALENTop: Resection vs continued Atezo/Bev in locally advanced HCC (Phase III) 3️⃣ Toripalimab + Lenvatinib + GEMOX: Neoadjuvant combo

🚨 Don’t miss! #ESMO25 | #NETs Mini Oral Session 🕣 08:30–10:00 1️⃣ ZG006 (Phase II): Trispecific T-cell engager (DLL3/DLL3/CD3) in refractory NEC – early efficacy. 2️⃣ ZG005 + EP (Phase II): 1L NEC combo showing enhanced activity vs chemo alone. 3️⃣ Triapine + ¹⁷⁷Lu-DOTATATE

Irish connections #ESMO25 presidential dinner from Medical school UCC Ireland to UAE, Beaumont & St James’s hospital to Princess Margaret Cancer Centre & The Christie NHS Lizzy Smyth Grainne O'Kane

Combined data: N=110, FGFR2 altered CCA treated with tinengotinib, presented by Milind Javle #ESMO25 ; N.B. PFS 6 mo & OS 17 mo for pts refractory/relapsed to FGFR2 inhibitors; FIRST-308 enrolling. Need option for these pts previously treated Cholangiocarcinoma Foundation AMMF

Interesting presentation (Dr Susan Galbraith): potential of T cell engagers in solid tumours/others #ESMO25 - need to increase efficacy + reduce toxicities (cytokine release syndrome); potential for CD8 guided T cell engagers. Promise in NEC Neuroendocrine Cancer UK #NotJustNECancer

Neoadjuvant Toripalimab Plus Lenvatinib and GEMOX in Resectable, High-Risk iCCCA: Phase II-III Trial #ESMO25 #ESMOAmbassadors 👉 EFS: 8 vs 18mo 🧐Strong signal for neoadjuvant therapy in BTC, more trials to come.. @myesmo

ctDNA session #ESMO25 with Melissa Frizziero discussing evolving field of early detection; ctDNA 10% of cfDNA. Emerging data in colorectal ca; minimal residual disease & early relapse & challenging decisions when identify ctDNA increase in adv disease The Christie NHS

Fellow alumni The Christie NHS at #ESMO25 growing & spreading their wings & working to educate & change outcomes for patients they treat Melissa Frizziero Rille Fabio Gomes

👑DYNAMIC-III ctDNA(-) cohort Presidential 3 #ESMO25 ESMO - Eur. Oncology ➡️ctDNA-guided adjuvant ChT de-escalation in stage-III colon cancer ✅de-escalation may be non-inferior in clinical low-risk (T1-3N1) tumours #cancer #oncology #MedX OncoAlert